FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 531 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Rediscovered Drugs Hit Leukemia from Two Different Angles July 21, 2020 FDA Approves Second CAR T-Cell Therapy for Lymphoma May 22, 2018 Zucchini everywhere October 9, 2020 Mediterranean Diet Associated with a Higher Probability of Response in Patients... February 28, 2023 Load more HOT NEWS Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers New Research in Treating Lymphoma and Improving Equity in Cancer Clinical... Foodie Friday: Watermelon Fruit Pizza Determining Fluid Requirements
